{"nctId":"NCT00890721","briefTitle":"Study of Pain Control in Hemorrhoidectomy","startDateStruct":{"date":"2009-05"},"conditions":["Hemorrhoid"],"count":189,"armGroups":[{"label":"SKY0402","type":"EXPERIMENTAL","interventionNames":["Drug: SKY0402"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SKY0402","otherNames":["EXPAREL"]},{"name":"Placebo","otherNames":["saline 0.9%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age \\> 18 years of age at the Screening visit\n* American Society of Anesthesiologists (ASA) class 1-3\n* Scheduled to have a two or three column excisional hemorrhoidectomy under general anesthesia using the Milligan-Morgan technique\n* For female subjects, surgically sterile or at least two years menopausal, or using an acceptable method of birth control; must have a documented negative blood or urine pregnancy test within 24 hours before surgery\n* Clinical lab values less than or equal to twice the upper limit of normal or, if abnormal, deemed not clinically significant per the Investigator.\n* Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments\n* Able to speak, read, and understand the language of all subject-facing documents, including the ICF and study questionnaires\n* Able and willing to comply with all study visits and procedures\n\nExclusion Criteria:\n\n* Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component\n* Body weight less than 50 kilograms (110 pounds)\n* History of hypersensitivity or idiosyncratic reactions or amide-type local anesthetics, opioids, or propofol\n* Current painful physical condition or concurrent surgery other than hemorrhoids that may require analgesic treatment (such as non-steroidal anti-inflammatory drug \\[NSAID\\], opioid, selective serotonin reuptake inhibitor \\[SSRI\\], tricyclic antidepressant, gabapentin, pregabalin) in the postoperative period for pain that is not strictly related to the hemorrhoidectomy procedure and may confound the postoperative assessments\n* Concurrent fissurectomy\n* Use of any NSAID including selective COX-2 inhibitor, opioid, SSRI, tricyclic antidepressant, gabapentin, or pregabalin within three days of surgery\n* Use of acetaminophen within 24 hours of surgery\n* Chronic users of analgesic medications, including taking opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week\n* History of, suspected, or known addiction to or abuse of drugs or alcohol within the past two years\n* Current use of glucocorticosteroids or use of glucocorticoids within one month of enrollment into this study\n* HIV infection or hepatitis\n* Currently pregnant, nursing, or planning to become pregnant during the course of the study or within one month of study drug administration\n* Any psychiatric, psychological, medical, or laboratory condition that the investigator feels makes the subject an inappropriate candidate for this clinical trial\n* Subjects who have received another investigational drug within the longer of the last 30 days or 10 elimination half-lives\n* Previous participation in a SKY0402 study\n* Failure to pass drug and alcohol screen","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.","description":"To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: \"On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.8","spread":"10.7"},{"groupId":"OG001","value":"202.5","spread":"10.7"}]}]}]},{"type":"SECONDARY","title":"Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":94},"commonTop":["Painful defaecation"]}}}